| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 2.70 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Nasopharyngeal Cancer Market Analysis
The Global Nasopharyngeal Cancer Market is expected to register a CAGR of 2.7% during the forecast period.
The COVID-19 pandemic impacted the global nasopharyngeal cancer (NPC) market. For instance, a November 2021 article by NCBI stated that the COVID-19 period saw a delay in the diagnosis of head and neck malignancies in comparison to the pre-COVID-19 period.Thus, the decrease in diagnosis of such patients reduced the number of surgeries and treatments, thereby affecting the market demand for the therapies among the end users. However, in the current scenario, it was expected that with the decreasing COVID-19 cases and the reopening of surgical and diagnosis centers globally, the market would witness significant growth over the forecast period.
The growth of the studied market is being fueled by the increasing number of cases of nasopharyngeal cancer and the growing awareness of treatment and diagnosis among the general public. Both of these things are expected to keep the market growing.
The American Cancer Society's revised data, released in August 2022, reported that throughout life, the risk of NPC increases slowly, but people of any age get the disease, including children. In places with a high risk of NPC, like China, people are often diagnosed between 45 and 59 years old, when they are at their peak. In places with a low risk of NPC, like the United States, cases are more common in young adults (15 to 24 years old), then drop until another peak between 65 and 79 years old.
Also, the source mentioned above says that NPC is much more common in some parts of South Asia, the Middle East, and North Africa.Native Americans in the Arctic also experience it more frequently. Additionally, the World Cancer Research Fund International (WCRF) data updated in 2022 shows that NPC is the 22nd most prevalent cancer in the world, and in terms of prevalence, it ranks 22nd among cancers in women and 18th among cancers in men. As per the WCRF, around 133,000 new NPC cases were diagnosed globally in 2020. Thus, to coordinate with the disease burden, the government and major companies are focusing more on developing therapies and drugs. This is anticipated to drive market growth.
During the analysis period, the market also grew because there were more research and development (R&D) activities, collaborations, strategic partnerships, product approvals, and product launches.For instance, the Food and Drug Administration (FDA) accepted a biologics license application (BLA) in July 2022 for toripalimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma.The BLA will be reviewed over the next 6 months, with a prescription drug user-free act date of December 23, 2022, and a launch in the first quarter of 2023 after the approval. Thus, such developments in the market are anticipated to fuel market growth.
So, the studied market is likely to grow because there are more cases of nasopharyngeal cancer and more people are becoming aware of how to treat and diagnose the disease. But the high costs and bad side effects of the treatments are likely to slow the growth of the market over the next few years.
Nasopharyngeal Cancer Market Trends
Chemotherapy Segment is Expected to Witness Significant Growth Over the Forecast Period
The application of anti-cancer medications is known as chemotherapy (or "chemo"). According to American Cancer Society data updated in August 2022, for NPC, these medications are typically administered intravenously (IV) or orally as an infusion. The demand for chemotherapy is increasing with the increasing prevalence of NPC among the target population globally. The source also reported that there may be up to 25 to 30 cases per 100,000 men and 15 to 20 cases per 100,000 women in various regions of China. Thus, it is expected to fuel segment growth over the forecast period.
The research article published by the American Society of Clinical Oncology (ASCO) in April 2022 reported that the standard treatment for people with recurrent or metastatic NPC is a combination of chemotherapy using gemcitabine (Gemzar) and cisplatin (available as a generic drug), and as per the researchers, when Tislelizumab was used in combination with chemotherapy, it helped people with advanced NPC live longer.
In addition, the research article published by NCBI in January 2022 reported that the addition of chemotherapy reduced the risk of death, with an absolute survival increase in children aged 5 and older of 6.1% and 8.4%, respectively. Thus, such research in favor of chemotherapy is anticipated to drive segment growth.
Furthermore, the companies in the market are prioritizing product development and innovation to bring advanced therapies to NPC sufferers. Continuous product approvals are one of the major factors bolstering the segment's growth. For instance, in June 2022, the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) using BeiGene's tislelizumab and chemotherapy will be approved by the China National Medical Products Administration (NMPA). As a result, related developments and clinical trials for several chemotherapy drugs are expected to increase, driving segment growth.
Thus, due to the rising incidence of NPCs and new product launches, the chemotherapy segment is poised to witness growth over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Witness Significant Growth Over the Forecast Period.
North America is expected to witness significant growth over the forecast period owing to the rising prevalence of nasopharyngeal cancer cases and the high awareness among the population towards treatment and diagnosis in North American countries. Also, the region is dominated by the presence of key market players, which leads to technological advances and the release of new products, which drive the growth of the studied market over the next few years.
The rising cases of NPC in Canada are increasing the demand for its drugs and, thus, driving the growth of the studied market. For instance, the Cancer Genobocan database in 2020 reported that 298 NPC cases are expected to be reported in Canada in the year 2025, and this number is expected to increase by 398 by 2040.
Moreover, an article published by the journal Cancer Medicine in February 2022 reported that Mexico has reported a significant increase in NPC cases over the past decade. Thus, increasing cancer cases are increasing the demand for NPC drugs and thus driving the growth of the studied market in the region.
Also, the growth of the studied market in the region is being driven by regulatory approvals for the release of new drugs and research.For instance, in November 2021, the USFDA granted priority review to the first-line toripalimab regimen in advanced nasopharyngeal carcinoma. a biologics license application (BLA) for the combination of toripalimab (Tuoyi) plus gemcitabine and cisplatin for patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
Thus, the increasing number of NPC cases and the clinical studies for the development of a new drug to treat NPC in the region are expected to accelerate the market's growth.
Get Analysis on Important Geographic Markets
Download PDF
Nasopharyngeal Cancer Industry Overview
Since there are only a few companies in the world, the market for nasopharyngeal cancer is not very competitive. The studied market consists of many global and regional market players, which hold most of the market shares and are well known. Some of the market players in the studied market are Biocon Limited, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals, F. Hoffman-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi, Theravectys SA, and Eli Lilly and Company.
Nasopharyngeal Cancer Market Leaders
-
Bristol Myers Squibb
-
Eli Lilly and Company
-
Merck & Co., Inc.
-
Novartis AG
-
GlaxoSmithKline (GSK) PLC
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Nasopharyngeal Cancer Market News
- June 2022: KMC clinics in Kolkata, India, started cancer screening, including nasopharyngeal cancer under the head and neck division. The screening program was launched in collaboration with the Indian Medical Association (IMA), the Indian Dental Association (IDA), and Medica Superspecialty Hospital. And it is expected to be carried out at all 16 centers under KMC.
- January 2022: Wistar Institute launched a phase 2 trial to examine the safety and efficacy of the oral inhibitor VK-2019 in patients with advanced Epstein-Barr virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma. The trial is being led by researchers at the Stanford University School of Medicine.
Nasopharyngeal Cancer Industry Segmentation
As per the scope of the report, nasopharyngeal cancer is a disease in which cancer cells form in the tissues of the nasopharynx (the upper part of the throat behind the nose). The risk of nasopharyngeal cancer can be affected by many things, including one's race and whether or not they have been exposed to the Epstein-Barr virus. Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), End User (Hospitals and Clinics, Ambulatory Surgery Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America) are the segments of the Nasopharyngeal Cancer Market. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Therapy | Chemotherapy | ||
| Immunotherapy | |||
| Radiation Therapy | |||
| Other Therapies | |||
| By End-Users | Hospitals and Clinics | ||
| Ambulatory Surgery Centers | |||
| Other End-Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Nasopharyngeal Cancer Market Research FAQs
What is the current Global Nasopharyngeal Cancer Market size?
The Global Nasopharyngeal Cancer Market is projected to register a CAGR of 2.7% during the forecast period (2025-2030)
Who are the key players in Global Nasopharyngeal Cancer Market?
Bristol Myers Squibb, Eli Lilly and Company, Merck & Co., Inc., Novartis AG and GlaxoSmithKline (GSK) PLC are the major companies operating in the Global Nasopharyngeal Cancer Market.
Which is the fastest growing region in Global Nasopharyngeal Cancer Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Nasopharyngeal Cancer Market?
In 2025, the North America accounts for the largest market share in Global Nasopharyngeal Cancer Market.
What years does this Global Nasopharyngeal Cancer Market cover?
The report covers the Global Nasopharyngeal Cancer Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Nasopharyngeal Cancer Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Nasopharyngeal Cancer Industry Report
Statistics for the 2025 Global Nasopharyngeal Cancer market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Global Nasopharyngeal Cancer analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
